Proviron

[mands]

Dugeroglu H, Ozturk M, Atmaca M, Seven I. Mesterolone treatment of aging male syndrome improves lower urinary tract symptoms. J Pak Med Assoc. 2014;64(12):1366-9. http://jpma.org.pk/full_article_text.php?article_id=7099

OBJECTIVE: To investigate the effects of mesterolone on prostate in patients treated for aging male syndrome.

METHODS: The cross-sectional study was conducted from June to September, 2009, at endocrinology and metabolism department of Yuzuncu Yil University, Van, Turkey, and comprised patients with symptoms of aging male syndrome and/or low testosterone.

They were given mesterolone 50 mg/day per oral for two months. Aging Male Symptoms and International Prostate Symptom Score questionaires and prostate-related quality of life scores were completed and prostate ultrasonography (USG) was performed before and after the treatment.

Total testosterone, free testosterone, gonadotropins, estradiol, prolactin, sex-hormone binding globulin, as well as total and free prostate-specific antigen were also studied.

RESULTS: Of the 34 patients in the study, 22(64.70%) had their prostate volume increased, while 12(35.29%) had it decreased. The change, however, was not statistically significant (p<0.098). Mesterolone significantly improved Aging Male Symptoms, International Prostate Symptom and prostate-related quality of life scores (p<0.001). These improvements though significant were independent of the changes in prostate volume.

Total testosterone, sex-hormone binding globulin andestradiol decreased, while free testosterone showed no change (p<0.002, p<0.001, p<0.024, p<0.337). The fraction of free testosterone increased (p<0.001), while total and free prostate-specific antigen did not change (p<0.368 and p<0.841).

CONCLUSION: Mesterolone proved to be a safe alternative in the treatment of Aging Male Syndrome. It also improved lower urinary tract symptoms and prostate-related quality of life.

Thanks for the post @Michael Scally MD

mands

 

[Dr JIM]

Dugeroglu H, Ozturk M, Atmaca M, Seven I. Mesterolone treatment of aging male syndrome improves lower urinary tract symptoms. J Pak Med Assoc. 2014;64(12):1366-9. http://jpma.org.pk/full_article_text.php?article_id=7099

OBJECTIVE: To investigate the effects of mesterolone on prostate in patients treated for aging male syndrome.

METHODS: The cross-sectional study was conducted from June to September, 2009, at endocrinology and metabolism department of Yuzuncu Yil University, Van, Turkey, and comprised patients with symptoms of aging male syndrome and/or low testosterone.

They were given mesterolone 50 mg/day per oral for two months. Aging Male Symptoms and International Prostate Symptom Score questionaires and prostate-related quality of life scores were completed and prostate ultrasonography (USG) was performed before and after the treatment.

Total testosterone, free testosterone, gonadotropins, estradiol, prolactin, sex-hormone binding globulin, as well as total and free prostate-specific antigen were also studied.

RESULTS: Of the 34 patients in the study, 22(64.70%) had their prostate volume increased, while 12(35.29%) had it decreased. The change, however, was not statistically significant (p<0.098). Mesterolone significantly improved Aging Male Symptoms, International Prostate Symptom and prostate-related quality of life scores (p<0.001). These improvements though significant were independent of the changes in prostate volume.

Total testosterone, sex-hormone binding globulin andestradiol decreased, while free testosterone showed no change (p<0.002, p<0.001, p<0.024, p<0.337). The fraction of free testosterone increased (p<0.001), while total and free prostate-specific antigen did not change (p<0.368 and p<0.841).

CONCLUSION: Mesterolone proved to be a safe alternative in the treatment of Aging Male Syndrome. It also improved lower urinary tract symptoms and prostate-related quality of life.

Nice follow up Doc.

I suspect the reason "an INCREASE of fractional FT" was observed, was a result of a DECREASE in TT.

No wonder this AAS primarily seems to improve the suppressed libido of psych patients

 

[ddp7]

Nice follow up Doc.

I suspect the reason "an INCREASE of fractional FT" was observed, was a result of a DECREASE in TT.

No wonder this AAS primarily seems to improve the suppressed libido of psych patients

Oldie but goodie thread.

Seems to be the behavior of average bber forum user is not the typical or normal behavior.

Then have a looot of sense the link between test cycle and heart attack; bbers behaviors have a relevant in this disease I mean from a wellness view heart attack is the result of biology and behavior.

Then DHT( yeah the "evil") IS the future.

American society of anti aging

Testosterone and Heart Disease

Feel free of explain your contra argues :^)

 

[ddp7]

And more facts in this way (PIERRE BOURDIEU is the basis of carl stempel)

Does Your Workout Say Something About Your Social Class?

 

[ddp7]

original source:

How the Other Half Lifts: What Your Workout Says About Your Social Class